메뉴 건너뛰기




Volumn 133, Issue 3, 2014, Pages 427-432

Efficacy and safety of AEZS-108 (INN: Zoptarelin Doxorubicin Acetate) an LHRH agonist linked to doxorubicin in women with platinum refractory or resistant ovarian cancer expressing LHRH receptors: A multicenter Phase II trial of the ago-study group (AGO GYN 5)

(10)  Emons, Günter a   Gorchev, Grigor b   Sehouli, Jalid c   Wimberger, Pauline d,j   Stähle, Anne e,k   Hanker, Lars f,l   Hilpert, Felix g   Sindermann, Herbert h   Gründker, Carsten a   Harter, Philipp i,m  


Author keywords

LHRH receptor targeted; Ovarian cancer; Platinum refractory; Platinum resistant; Targeted chemotherapy

Indexed keywords

CA 125 ANTIGEN; DEXAMETHASONE; GAMMA GLUTAMYLTRANSFERASE; GONADORELIN RECEPTOR; PLATINUM; ZOPTARELIN DOXORUBICIN;

EID: 84901687669     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2014.03.576     Document Type: Article
Times cited : (44)

References (25)
  • 2
    • 0007428697 scopus 로고    scopus 로고
    • Eco European Cancer Observatory [accessed on 25/03/2013]
    • ECO, European Cancer Observatory International Agency for Research on Cancer http://eu-cancer.iarc.fr [accessed on 25/03/2013]
    • International Agency for Research on Cancer
  • 3
    • 84891701459 scopus 로고    scopus 로고
    • Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer
    • 10.1002/14651858. CD006910.pub2 [Art. No.: CD006910]
    • T.A. Lawrie, A. Bryant, A. Cameron, E. Gray, and J. Morrison Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer Cochrane Database Syst Rev 7 2013 10.1002/14651858. CD006910.pub2 [Art. No.: CD006910]
    • (2013) Cochrane Database Syst Rev , Issue.7
    • Lawrie, T.A.1    Bryant, A.2    Cameron, A.3    Gray, E.4    Morrison, J.5
  • 4
    • 84869109927 scopus 로고    scopus 로고
    • Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer
    • N. Colombo, E. Kutarska, M. Dimopoulos, D.-S. Bae, I. Rzepka-Gorskar, and M. Bidzinski et al. Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer J Clin Oncol 30 2012 3841 3847
    • (2012) J Clin Oncol , vol.30 , pp. 3841-3847
    • Colombo, N.1    Kutarska, E.2    Dimopoulos, M.3    Bae, D.-S.4    Rzepka-Gorskar, I.5    Bidzinski, M.6
  • 5
    • 63449129599 scopus 로고    scopus 로고
    • Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer. A combined exploratory analysis of three prospectively randomized phase III multicenter trials by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancer de l'Ovaire (GINECO)
    • A. du Bois, A. Reuss, E. Pujade-Lauraine, P. Harter, I. Ray-Coquard, and J. Pfisterer et al. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer. A combined exploratory analysis of three prospectively randomized phase III multicenter trials by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancer de l'Ovaire (GINECO) Cancer 115 2009 1234 1244
    • (2009) Cancer , vol.115 , pp. 1234-1244
    • Du Bois, A.1    Reuss, A.2    Pujade-Lauraine, E.3    Harter, P.4    Ray-Coquard, I.5    Pfisterer, J.6
  • 6
    • 84867114224 scopus 로고    scopus 로고
    • The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy
    • L.C. Hanker, S. Loibl, N. Burchardi, J. Pfisterer, W. Meier, and E. Pujade-Lauraine et al. The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy Ann Oncol 23 2012 2605 2612
    • (2012) Ann Oncol , vol.23 , pp. 2605-2612
    • Hanker, L.C.1    Loibl, S.2    Burchardi, N.3    Pfisterer, J.4    Meier, W.5    Pujade-lauraine, E.6
  • 7
    • 79951990944 scopus 로고    scopus 로고
    • Topotecan weekly versus conventional 5-day schedule in patients with platinum-resistant ovarian cancer: A randomized multicenter phase II trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group
    • J. Sehouli, D. Stengel, P. Harter, C. Kurzeder, T. Bogenrieder, and S. Markmann et al. Topotecan weekly versus conventional 5-day schedule in patients with platinum-resistant ovarian cancer: a randomized multicenter phase II trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group J Clin Oncol 29 2011 242 248
    • (2011) J Clin Oncol , vol.29 , pp. 242-248
    • Sehouli, J.1    Stengel, D.2    Harter, P.3    Kurzeder, C.4    Bogenrieder, T.5    Markmann, S.6
  • 8
    • 0032935902 scopus 로고    scopus 로고
    • Cytotoxic analogs of luteinizing hormone-releasing hormone bind with high affinity to human breast cancers
    • G. Halmos, A. Nagy, N. Lamharzi, and A.V. Schally Cytotoxic analogs of luteinizing hormone-releasing hormone bind with high affinity to human breast cancers Cancer Lett 136 1999 129 136
    • (1999) Cancer Lett , vol.136 , pp. 129-136
    • Halmos, G.1    Nagy, A.2    Lamharzi, N.3    Schally, A.V.4
  • 9
    • 0141456444 scopus 로고    scopus 로고
    • Targeted doxorubicin-containing luteinizing hormone-releasing hormone analogue AN-152 inhibits the growth of doxorubicin-resistant MX-1 human breast cancers
    • A.M. Bajo, A.V. Schally, G. Halmos, and A. Nagy Targeted doxorubicin-containing luteinizing hormone-releasing hormone analogue AN-152 inhibits the growth of doxorubicin-resistant MX-1 human breast cancers Clin Cancer Res 9 2003 3742 3748
    • (2003) Clin Cancer Res , vol.9 , pp. 3742-3748
    • Bajo, A.M.1    Schally, A.V.2    Halmos, G.3    Nagy, A.4
  • 10
    • 0031438761 scopus 로고    scopus 로고
    • Growth-inhibitory actions of analogues of luteinizing hormone releasing hormone on tumor cells
    • G. Emons, O. Ortmann, K.D. Schulz, and A.V. Schally Growth-inhibitory actions of analogues of luteinizing hormone releasing hormone on tumor cells Trends Endocrinol Metab 8 1997 355 362
    • (1997) Trends Endocrinol Metab , vol.8 , pp. 355-362
    • Emons, G.1    Ortmann, O.2    Schulz, K.D.3    Schally, A.V.4
  • 11
    • 0034322411 scopus 로고    scopus 로고
    • Receptor mediated antiproliferative effects of the cytotoxic LHRH agonist AN-152 in human ovarian and endometrial cancer cell lines
    • S. Westphalen, G. Kotulla, F. Kaiser, W. Krauss, G. Werning, and H.P. Elsässer et al. Receptor mediated antiproliferative effects of the cytotoxic LHRH agonist AN-152 in human ovarian and endometrial cancer cell lines Int J Oncol 17 2000 1063 1069
    • (2000) Int J Oncol , vol.17 , pp. 1063-1069
    • Westphalen, S.1    Kotulla, G.2    Kaiser, F.3    Krauss, W.4    Werning, G.5    Elsässer, H.P.6
  • 12
    • 67651113824 scopus 로고    scopus 로고
    • Luteinizing hormone-releasing hormone receptor-targeted chemotherapy using AN-152
    • G. Emons, H. Sindermann, J. Engel, A. Schally, and C. Gründker et al. Luteinizing hormone-releasing hormone receptor-targeted chemotherapy using AN-152 Neuroendocrinology 90 2009 15 18
    • (2009) Neuroendocrinology , vol.90 , pp. 15-18
    • Emons, G.1    Sindermann, H.2    Engel, J.3    Schally, A.4    Gründker, C.5
  • 13
    • 0036737652 scopus 로고    scopus 로고
    • Antitumor effects of the cytotoxic luteinizing hormone-releasing hormone analog AN-152 on human endometrial and ovarian cancers xenografted into nude mice
    • C. Grundker, P. Volker, F. Griesinger, A. Ramaswamy, A. Nagy, and A.V. Schally et al. Antitumor effects of the cytotoxic luteinizing hormone-releasing hormone analog AN-152 on human endometrial and ovarian cancers xenografted into nude mice Am J Obstet Gynecol 187 2002 528 537
    • (2002) Am J Obstet Gynecol , vol.187 , pp. 528-537
    • Grundker, C.1    Volker, P.2    Griesinger, F.3    Ramaswamy, A.4    Nagy, A.5    Schally, A.V.6
  • 14
    • 78149359898 scopus 로고    scopus 로고
    • Dose escalation and pharmacokinetic study of AEZS-108 (AN-152), an LHRH agonist linked to doxorubicin, in women with LHRH receptor-positive tumors
    • G. Emons, M. Kaufmann, G. Gorchev, V. Tsekova, C. Gründker, and A.R. Günthert et al. Dose escalation and pharmacokinetic study of AEZS-108 (AN-152), an LHRH agonist linked to doxorubicin, in women with LHRH receptor-positive tumors Gynecol Oncol 119 2010 457 461
    • (2010) Gynecol Oncol , vol.119 , pp. 457-461
    • Emons, G.1    Kaufmann, M.2    Gorchev, G.3    Tsekova, V.4    Gründker, C.5    Günthert, A.R.6
  • 15
    • 0034594628 scopus 로고    scopus 로고
    • New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
    • P. Therasse, S.G. Arbuck, E.A. Eisenhauer, J. Wanders, R.S. Kaplan, and L. Rubinstein et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
    • (2000) J Natl Cancer Inst , vol.92 , pp. 205-216
    • Therasse, P.1    Arbuck, S.G.2    Eisenhauer, E.A.3    Wanders, J.4    Kaplan, R.S.5    Rubinstein, L.6
  • 17
    • 79953041153 scopus 로고    scopus 로고
    • Targeted chemotherapy for triple-negative breast cancers via LHRH receptor
    • C. Fost, F. Duwe, M. Hellriegel, S. Schweyer, G. Emons, and Carsten Gründker et al. Targeted chemotherapy for triple-negative breast cancers via LHRH receptor Oncol Rep 25 2011 1481 1487
    • (2011) Oncol Rep , vol.25 , pp. 1481-1487
    • Fost, C.1    Duwe, F.2    Hellriegel, M.3    Schweyer, S.4    Emons, G.5    Gründker, C.6
  • 18
    • 79956076619 scopus 로고    scopus 로고
    • Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA-125 agreed by the Gynecological Cancer Intergroup (GCIG)
    • G.J. Rustin, I. Vergote, E. Eisenhauer, E. Pujade-Lauraine, M. Quinn, and T. Thigpen et al. Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA-125 agreed by the Gynecological Cancer Intergroup (GCIG) Int J Gynecol Cancer 21 2011 419 423
    • (2011) Int J Gynecol Cancer , vol.21 , pp. 419-423
    • Rustin, G.J.1    Vergote, I.2    Eisenhauer, E.3    Pujade-Lauraine, E.4    Quinn, M.5    Thigpen, T.6
  • 19
    • 0032582620 scopus 로고    scopus 로고
    • Optimal flexible designs in phase II clinical trials
    • T.T. Chen, and T.H. Ng Optimal flexible designs in phase II clinical trials Stat Med 17 1998 2301 2312
    • (1998) Stat Med , vol.17 , pp. 2301-2312
    • Chen, T.T.1    Ng, T.H.2
  • 20
    • 0035879099 scopus 로고    scopus 로고
    • Recurrent epithelial ovarian carcinoma: A randomized phase III study of pegylated liposomal doxorubicin versus topotecan
    • A.N. Gordon, J.T. Fleagle, D. Guthrie, D.E. Parkin, M.E. Gore, and A.J. Lacave et al. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan J Clin Oncol 19 2001 3312 3322
    • (2001) J Clin Oncol , vol.19 , pp. 3312-3322
    • Gordon, A.N.1    Fleagle, J.T.2    Guthrie, D.3    Parkin, D.E.4    Gore, M.E.5    Lacave, A.J.6
  • 22
    • 0141940302 scopus 로고    scopus 로고
    • Phase II study of cetrorelix, a luteinizing hormone-releasing hormone antagonist in patients with platinum-resistant ovarian cancer
    • C.F. Verschraegen, S. Westphalen, W. Hu, E. Loyer, A. Kudelka, and P. Völker et al. Phase II study of cetrorelix, a luteinizing hormone-releasing hormone antagonist in patients with platinum-resistant ovarian cancer Gynecol Oncol 90 2003 552 559
    • (2003) Gynecol Oncol , vol.90 , pp. 552-559
    • Verschraegen, C.F.1    Westphalen, S.2    Hu, W.3    Loyer, E.4    Kudelka, A.5    Völker, P.6
  • 23
    • 84886092119 scopus 로고    scopus 로고
    • Folate and folate receptor alpha antagonists mechanism of action in ovarian cancer
    • C.L. Walters, R.C. Arend, D.K. Armstrong, R.W. Naumann, and R.D. Alvarez et al. Folate and folate receptor alpha antagonists mechanism of action in ovarian cancer Gynecol Oncol 131 2013 493 498
    • (2013) Gynecol Oncol , vol.131 , pp. 493-498
    • Walters, C.L.1    Arend, R.C.2    Armstrong, D.K.3    Naumann, R.W.4    Alvarez, R.D.5
  • 24
    • 84869799142 scopus 로고    scopus 로고
    • Phase II study of bevacizumab with liposomal doxorubicin for patients with platinum- and taxane-resistant ovarian cancer
    • C.F. Verschraegen, S. Czok, C.Y. Muller, L. Boyd, S.J. Lee, and T. Rutledge et al. Phase II study of bevacizumab with liposomal doxorubicin for patients with platinum- and taxane-resistant ovarian cancer Ann Oncol 23 2012 3104 3110
    • (2012) Ann Oncol , vol.23 , pp. 3104-3110
    • Verschraegen, C.F.1    Czok, S.2    Muller, C.Y.3    Boyd, L.4    Lee, S.J.5    Rutledge, T.6
  • 25
    • 84866493383 scopus 로고    scopus 로고
    • AURELIA: A randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC)
    • [abstr LBA 5002]
    • E. Pujade-Lauraine, F. Hilpert, B. Weber, A. Reuss, A. Poveda, and G. Kristensen et al. AURELIA: a randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC) J Clin Oncol 30 Suppl. 18 2012 [abstr LBA 5002]
    • (2012) J Clin Oncol , vol.30 , Issue.SUPPL. 18
    • Pujade-Lauraine, E.1    Hilpert, F.2    Weber, B.3    Reuss, A.4    Poveda, A.5    Kristensen, G.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.